Description: ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company's second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also developing multiple precision medicines targeting other cancer resistance mechanisms. The company was founded in 2014 and is headquartered in South San Francisco, California.
Home Page: www.oricpharma.com
ORIC Technical Analysis
240 East Grand Avenue
South San Francisco,
CA
94080
United States
Phone:
650 388 5600
Officers
| Name | Title |
|---|---|
| Dr. Richard A. Heyman Ph.D. | Co-Founder, Independent Chairman & Member of Scientific Advisory Board |
| Dr. Jacob M. Chacko M.B.A., M.D. | Pres, CEO & Director |
| Mr. Dominic G. Piscitelli CPA, CPA, M.B.A. | Chief Financial Officer |
| Dr. Pratik S. Multani M.D., M.S. | Chief Medical Officer |
| Dr. Charles L. Sawyers B.A., BA, M.D., Ph.D. | Co-Founder & Member of Scientific Advisory Board |
| Dr. Scott W. Lowe Ph.D. | Co-Founder & Member of Scientific Advisory Board |
| Dr. Lori Sickels Friedman Ph.D. | Chief Scientific Officer |
| Dr. Christian V. Kuhlen Esq., J.D., M.D. | Gen. Counsel |
| Mr. Daniel Iazzetti | VP & Head of People |
| Dr. Edna Chow Maneval | Sr. VP of Clinical Devel. |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.6485 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2020-04-24 |
| Fiscal Year End: | December |
| Full Time Employees: | 88 |